The Price of Progress: Cost, Access, and Adoption of Novel Cardiovascular Drugs in Clinical Practice
出版年份 2021 全文链接
标题
The Price of Progress: Cost, Access, and Adoption of Novel Cardiovascular Drugs in Clinical Practice
作者
关键词
-
出版物
Current Cardiology Reports
Volume 23, Issue 11, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2021-10-02
DOI
10.1007/s11886-021-01598-w
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Cost-effectiveness and affordability of novel cardiovascular therapies: what physicians need to know
- (2021) Enrico Giuseppe Ferro et al. HEART
- Changes in List Prices, Net Prices, and Discounts for Branded Drugs in the US, 2007-2018
- (2020) Inmaculada Hernandez et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Tafamidis—A Pricey Therapy for a Not-So-Rare Condition
- (2020) Jerry H. Gurwitz et al. JAMA Cardiology
- Initial Experience Prescribing Commercial Tafamidis, the Most Expensive Cardiac Medication in History
- (2020) Ahmad Masri et al. JAMA Cardiology
- Response by Kazi et al to Letter Regarding Article, “Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy”
- (2020) Dhruv S. Kazi et al. CIRCULATION
- Trends in Utilization and Cost of Low-Density Lipoprotein Cholesterol–Lowering Therapies Among Medicare Beneficiaries
- (2020) Andrew Sumarsono et al. JAMA Cardiology
- A Health Opportunity Cost Threshold for Cost-Effectiveness Analysis in the United States
- (2020) David J. Vanness et al. ANNALS OF INTERNAL MEDICINE
- Cost-Effectiveness of Alirocumab
- (2019) Dhruv S. Kazi et al. ANNALS OF INTERNAL MEDICINE
- The Orphan Drug Act Revisited
- (2019) Shailin Thomas et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Reforming the Orphan Drug Act for the 21st Century
- (2019) Ameet Sarpatwari et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
- (2019) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prior Authorization Requirements for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Across US Private and Public Payers
- (2018) Jalpa A. Doshi et al.
- Adoption of Sacubitril/Valsartan for the Management of Patients With Heart Failure
- (2018) Lindsey R. Sangaralingham et al. Circulation-Heart Failure
- Health Insurance and Poverty in Trajectories of Out-of-Pocket Expenditure among Low-Income Middle-Aged Adults
- (2018) Eunsun Kwon et al. HEALTH SERVICES RESEARCH
- Prior Authorization Requirements for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Across US Private and Public Payers
- (2018) Jalpa A. Doshi et al. Circulation-Cardiovascular Quality and Outcomes
- Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
- (2018) Mathew S. Maurer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Alirocumab’s Price Reduction
- (2018) Sanket S. Dhruva et al. CIRCULATION
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
- (2017) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nationwide Coverage and Cost-Sharing for PCSK9 Inhibitors Among Medicare Part D Plans
- (2017) Dhruv S. Kazi et al. JAMA Cardiology
- Association of Prior Authorization and Out-of-pocket Costs With Patient Access to PCSK9 Inhibitor Therapy
- (2017) Ann Marie Navar et al. JAMA Cardiology
- Cost-Effectiveness of Dabigatran (150 mg Twice Daily) and Warfarin in Patients ≥65 Years With Nonvalvular Atrial Fibrillation
- (2016) Brian M. Salata et al. AMERICAN JOURNAL OF CARDIOLOGY
- Innovation–Innovation Tradeoffs in Drug Pricing
- (2016) Rachel E. Sachs et al. ANNALS OF INTERNAL MEDICINE
- Cost-Effectiveness of Sacubitril–Valsartan in Patients With Heart Failure With Reduced Ejection Fraction
- (2016) Alexander T. Sandhu et al. ANNALS OF INTERNAL MEDICINE
- The High Cost of Prescription Drugs in the United States
- (2016) Aaron S. Kesselheim et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease
- (2016) Dhruv S. Kazi et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Cost-effectiveness Analysis of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction
- (2016) Thomas A. Gaziano et al. JAMA Cardiology
- Hospitalizations and Deaths Among Adults With Cardiovascular Disease Who Underuse Medications Because of Cost
- (2016) Michele Heisler et al. MEDICAL CARE
- Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
- (2015) Jennifer G. Robinson et al. NEW ENGLAND JOURNAL OF MEDICINE
- ACC/AHA Statement on Cost/Value Methodology in Clinical Practice Guidelines and Performance Measures
- (2014) Jeffrey L. Anderson et al. CIRCULATION
- Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure
- (2014) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cost-Effectiveness of Dabigatran Compared With Warfarin for Stroke Prevention in Atrial Fibrillation
- (2013) James V. Freeman et al. ANNALS OF INTERNAL MEDICINE
- The Anatomy of Health Care in the United States
- (2013) Hamilton Moses et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- National Trends in Oral Anticoagulant Use in the United States, 2007 to 2011
- (2012) Kate Kirley et al.
- The Relative Cost-Effectiveness of Anticoagulants
- (2011) Jerry Avorn CIRCULATION
- Interpreting the Results of Cost-Effectiveness Studies
- (2008) David J. Cohen et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started